الصفحة الرئيسية>>Signaling Pathways>> Metabolism>> Factor Xa>>Rivaroxaban

Rivaroxaban (Synonyms: BAY 597939)

رقم الكتالوجGC13683

A selective inhibitor of Factor Xa

Products are for research use only. Not for human use. We do not sell to patients.

Rivaroxaban التركيب الكيميائي

Cas No.: 366789-02-8

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
47٫00
متوفر
5mg
59٫00
متوفر
10mg
86٫00
متوفر
50mg
171٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Rivaroxaban, 5-chloro-N-[[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl]thiophene-2-carboxamide, is a potent small-molecule inhibitor of factor Xa which is a coagulation factor at a critical juncture in the blood coagulation pathway resulting in the generation of thrombin and the formation of clot. Rivaroxaban binds to the Tyr288 in S1 pocket of factor Xa through the interaction of Tyr288 and the chlorine substituent of the chlorothiophene moiety. The inhibition is reversible (koff = 5x10-3s-1), rapid (kon = 1.7x107 mol/L-1 s-1), and in a concentration-dependent manner (Ki = 0.4 nmol/L). Rivaroxaban is currently being studied for the treatment of VTE, prevention of cardiovascular events in patients with acute coronary syndrome, prevention of stroke in patients with atrial fibrillation.

Reference

[1].Elisabeth Perzborn, Susanne Roehrig, Alexander Straub, Dagmar Kubitza, Wolfgang Mueck, and Volker Laux. Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol 2010; 30(3): 376-381

مراجعات

Review for Rivaroxaban

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Rivaroxaban

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.